Interventions against West Nile virus, Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus: Where are we?

Vector-Borne and Zoonotic Diseases

Volumn 10, Issue 7, 2010, Pages 709-718

  Kortekaas, Jeroen ^a   Ergönül, Önder ^b   Moormann, Rob J M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

antiviral; ARBO ZOONET; Crimean Congo hemorrhagic fever virus; Rift Valley fever virus; Vaccine; Vector; West Nile virus

Indexed keywords

64TRP VACCINE; ALPHAVIRUS VACCINE; ANTIMOSQUITO VACCINE; ANTIVIRUS AGENT; BM86 VACCINE; CANARYPOX VECTORED VACCINE; CLONE 13 VACCINE; CRIMEAN CONGO HEMORRHAGIC FEVER VACCINE; DNA VACCINE; DUVAXYN; FLUOROURACIL; GAVAC; INSECT VENOM; LIVE ATTENUATED RIFT VALLEY FEVER BUNYAVIRUS VACCINE; LIVE VACCINE; MULTIFERON; N ACETYL S NITROSOPENICILLAMINE; NUCLEOCAPSID PROTEIN; PLACEBO; PREVENILE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT PROTEIN; RECOMBITEK; RIBAVIRIN; RNA VACCINE; SALIVA PROTEIN; SMITHBURN VACCINE; SUBUNIT VACCINE; TICK BORNE ENCEPHALITIS VACCINE; TICKGARD; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS VACCINE; WEST NILE INNOVATOR; WEST NILE VACCINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BABESIOSIS; BLEEDING TENDENCY; BLOOD BRAIN BARRIER; CLINICAL EVALUATION; CLINICAL TRIAL; CRIMEAN CONGO HEMORRHAGIC FEVER; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNITY; IMMUNIZATION; INFECTION CONTROL; INTERVENTION STUDY; NAIRO VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SURVIVAL RATE; TICK BORNE ENCEPHALITIS; TURKEY (REPUBLIC); VIRUS STRAIN; VIRUS TRANSMISSION; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; PROTEIN SUBUNITS; RIFT VALLEY FEVER; VACCINES, SYNTHETIC; VIRAL VACCINES; WEST NILE FEVER;

CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; RIFT VALLEY FEVER VIRUS; WEST NILE VIRUS;

EID: 77957608945     PISSN: 15303667     EISSN: None     Source Type: Journal    
DOI: 10.1089/vbz.2010.0040     Document Type: Review

References (115)

1. Ahmed, J, Bouloy, M, Ergönül, Ö., Fooks, A, et al. International network for capacity building for the control of emerging viral vector-borne zoonotic diseases: ARBO-ZOONET. Euro Surveill 2009; 14:pii:19160.
2. Al-Hazmi, M, Ayoola, EA, Abdurahman, M, Banzal, S, et al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 2003; 36:245-252.
3. Allen, JR, Humphreys, SJ. Immunisation of guinea pigs and cattle against ticks. Nature 1979; 280:491-493.
4. Almeida, AP, Billingsley, PF. Induced immunity against the mosquito Anopheles stephensi (Diptera: Culicidae): effects of cell fraction antigens on survival, fecundity, and Plasmodium berghei (Eucoccidiida: Plasmodiidae) transmission. J Med Entomol 2002; 39:207-214.
5. Almeida, AP, Billingsley, PF. Induced immunity against the mosquito Anopheles stephensi Liston (Diptera: Culicidae): effects on mosquito survival and fecundity. Int J Parasitol 1998; 28:1721-1731.
6. Anderson, JF, Rahal, JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002; 8:107-108.
7. Andersson, I, Bladh, L, Mousavi-Jazi, M, Magnusson, KE, et al. Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J Virol 2004; 78: 4323-4329.
8. Andersson, I, Karlberg, H, Mousavi-Jazi, M, Martinez-Sobrido, L, et al. Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. J Med Virol 2008; 80:1397-1404.
9. Andersson, I, Lundkvist, A, Haller, O, Mirazimi, A. Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells. J Med Virol 2006; 78:216-222.
10. Barnard, BJ. Rift Valley fever vaccine - antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 1979; 50:155-157.
11. Barnard, BJ, Botha, MJ. An inactivated rift valley fever vaccine. J S Afr Vet Assoc 1977; 48:45-48.
12. Barzon, L, Squarzon, L, Cattai, M, Franchin, E, et al. West Nile virus infection in Veneto region, Italy, 2008-2009. Euro Surveill 2009; 14:pii:19289.
13. Bergeron, E, Albarino, CG, Khristova, ML, Nichol, ST. Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function. J Virol 2010; 84:216-226.
14. Bergeron, E, Vincent, MJ, Nichol, ST. Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity. J Virol 2007; 81:13271-13276.
15. Billecocq, A, Gauliard, N, Le May, N, Elliott, RM, et al. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 2008; 378:377-384.
16. Bird, BH, Albarino, CG, Hartman, AL, Erickson, BR, et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008; 82:2681-2691.
17. Bird, BH, Ksiazek, TG, Nichol, ST, Maclachlan, NJ. Rift Valley fever virus. J Am Vet Med Assoc 2009; 234:883-893.
18. Blitvich, BJ. Transmission dynamics and changing epidemiology of West Nile virus. Anim Health Res Rev 2008; 9:71-86.
19. Botros, B, Omar, A, Elian, K, Mohamed, G, et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 2006; 78:787-791.
20. Bouloy, M, Flick, R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res 2009; 84:101-118.
21. Bouloy, M, Janzen, C, Vialat, P, Khun, H, et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 2001; 75: 1371-1377.
22. Bridgen, A, Elliott, RM. Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. Proc Natl Acad Sci U S A 1996; 93:15400-15404.
23. Centers for Disease Control and Prevention. Viral hemorrhagic fever: initial management of suspected and confirmed cases. MMWR Morb Mortal Wkly Rep 1983; 32:27S-38S.
24. Chowers, MY, Lang, R, Nassar, F, Ben-David, D, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7:675-678.
25. Chu, JJ, Ng, ML. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J Biol Chem 2004; 279:54533-54541.
26. Coetzer, JA. The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res 1977; 44:205-211.
27. de Boer, SM, Kortekaas, J, Antonis, AF, Kant, J, et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 2010; 28:2330-2339.
28. Dempsey, PW, Allison, ME, Akkaraju, S, Goodnow, CC et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271:348-350.
29. Diamond, MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res 2009; 83:214-227.
30. Easterday, BC. Rift valley fever. Adv Vet Sci 1965; 10:65-127.
31. Eifan, SA, Elliott, RM. Mutational analysis of the Bunyamwera orthobunyavirus nucleocapsid protein gene. J Virol 2009; 83:11307-11317.
32. El Garch, H, Minke, JM, Rehder, J, Richard, S, et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol 2008; 123:230-239.
33. Ergönül, Ö. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006; 6:203-214.
34. Ergönül, Ö. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008; 78:125-131.
35. Ergönül, Ö., Celikbas, A, Dokuzoguz, B, Eren, S, et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39:284-287.
36. Ergönül, Ö., Whitehouse, CA, eds. Crimean-Congo Hemorrhagic Fever: A Global Perspective. Dordrecht, The Netherlands: Springer, 2007.
37. Fauquet, CM, Mayo, MA, Maniloff, J, Desselberger, U, et al Virus Taxonomy: Eighth Report of the International Committee on Taxonomy of Viruses. Academic Press, London: an imprint of Elsevier, 2005.
38. Findlay, GM, Daubney, R. The virus of Rift Valley fever or enzoö tic hepatitis. Lancet 1931; ii:1350-1351.
39. Fontenille, D, Traore-Lamizana, M, Diallo, M, Thonnon, J, et al. New vectors of Rift Valley fever in West Africa. Emerg Infect Dis 1998; 4:289-293.
40. Frank-Peterside, N. Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine - TSI-GSD 200. Afr J Med Med Sci 2000; 29:89-92.
41. Garcia, S, Crance, JM, Billecocq, A, Peinnequin, A, et al. Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds. J Clin Microbiol 2001; 39:4456-4461.
42. Gerrard, SR, Bird, BH, Albarino, CG, Nichol, ST. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 2007; 359:459-465.
43. Gerrard, SR, Nichol, ST. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 2007; 357:124-133.
44. Gomes, R, Teixeira, C, Teixeira, MJ, Oliveira, F, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A 2008; 105:7845-7850.
45. Gorchakov, R, Volkova, E, Yun, N, Petrakova, O, et al. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 2007; 366:212-225.
46. Gough, JM, Kemp, DH. Localization of a low abundance membrane protein (Bm86) on the gut cells of the cattle tick Boophilus microplus by immunogold labeling. J Parasitol 1993; 79:900-907.
47. Granwehr, BP, Lillibridge, KM, Higgs, S, Mason, PW, et al. West Nile virus: where are we now? Lancet Infect Dis 2004; 4:547-556.
48. Guy, B, Guirakhoo, F, Barban, V, Higgs, S, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-649.
49. Habjan, M, Penski, N, Spiegel, M, Weber, F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J Gen Virol 2008; 89:2157-2166.
50. Habjan, M, Penski, N, Wagner, V, Spiegel, M, et al. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology 2009a; 385:400-408.
51. Habjan, M, Pichlmair, A, Elliott, RM, Overby, AK. NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 2009b; 83:4365-4375.
52. Harrington, DG, Lupton, HW, Crabbs, CL, Peters, CJ, et al. Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am J Vet Res 1980; 41:1559-1564.
53. Hayes, CG. West Nile virus: Uganda, 1937, to New York City, 1999. Ann N Y Acad Sci 2001; 951:25-37.
54. Heise, MT, Whitmore, A, Thompson, J, Parsons, M, et al. An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 2009; 137:1309-1318.
55. Hoogstraal, H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol 1979; 15:307-417.
56. Huggins, JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11:S750-S761.
57. Hunter, P, Erasmus, BJ, Vorster, JH. Teratogenicity of a muta-genised Rift Valley fever virus (MVP 12) in sheep. Onder-stepoort J Vet Res 2002; 69:95-98.
58. Ikegami, T, Narayanan, K, Won, S, Kamitani, W, et al. Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional down-regulation of protein kinase PKR. Ann N Y Acad Sci 2009a; 1171:E75-E85.
59. Ikegami, T, Narayanan, K, Won, S, Kamitani, W, et al. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 2009b; 5:e1000287.
60. Ikegami, T, Won, S, Peters, CJ, Makino, S. Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 2006; 80:2933-2940.
61. Izadi, S, Salehi, M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J Infect Dis 2009; 62:11-15.
62. Jordan, I, Briese, T, Fischer, N, Lau, JY, et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000; 182:1214-1217.
63. Kamal, SA. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J 2009; 6:94.
64. Kortekaas, J, Dekker, A, de Boer, SM, Weerdmeester, K, et al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 2010; 28:2271-2276.
65. Kramer, LD, Li, J, Shi, PY. West Nile virus. Lancet Neurol 2007; 6:171-181.
66. Kunz, SE, Kemp, DH. Insecticides and acaricides: resistance and environmental impact. Rev Sci Tech 1994; 13:1249-1286.
67. Kutzler, MA, Weiner, DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9:776-788.
68. Labuda, M, Trimnell, AR, Lickova, M, Kazimirova, M, et al. An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog 2006; 2:e27.
69. Lorenzo, G, Martin-Folgar, R, Rodriguez, F, Brun, A. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 2008; 26:5255-5262.
70. Lowen, AC, Boyd, A, Fazakerley, JK, Elliott, RM. Attenuation of bunyavirus replication by rearrangement of viral coding and noncoding sequences. J Virol 2005; 79:6940-6946.
71. Madani, TA, Al-Mazrou, YY, Al-Jeffri, MH., Mishkhas, AA, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003; 37:1084-1092.
72. Malinoski, FJ, Hasty, SE, Ussery, MA, Dalrymple, JM. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res 1990; 13:139-149.
73. Mandell, RB, Koukuntla, R, Mogler, LJ, Carzoli, AK, et al. A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology 2009; 397:187-198.
74. Mardani, M, Jahromi, MK, Naieni, KH, Zeinali, M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36:1613-1618.
75. Martin, JE, Pierson, TC, Hubka, S, Rucker, S, et al A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007; 196:1732-1740.
76. McElroy, AK, Albarino, CG, Nichol, ST. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol J 2009; 6:125.
77. McIntosh, BM, Russell, D, dos Santos, I, Gear, JH. Rift Valley fever in humans in South Africa. S Afr Med J 1980; 58: 803-806.
78. Meegan, JM. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizootic and virological studies. Trans R Soc Trop Med Hyg 1979; 73:618-623.
79. Minke, JM, Siger, L, Karaca, K, Austgen, L, et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 2004; (18):221-230.
80. Monath, TP, Liu, J, Kanesa-Thasan, N, Myers, GA, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A 2006; 103:6694-6699.
81. Morrey, JD, Smee, DF, Sidwell, RW, Tseng, C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002; 55:107-116.
82. Morrill, JC, Carpenter, L, Taylor, D, Ramsburg, HH, et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 1991; 9:35-41.
83. Morrill, JC, Jennings, GB, Caplen, H, Turell, MJ, et al. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 1987; 48:1042-1047.
84. Morrill, JC, Mebus, CA, Peters, CJ. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997a; 58:1104-1109.
85. Morrill, JC, Mebus, CA, Peters, CJ. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 1997b; 58:1110-1114.
86. Moudy, RM, Meola, MA, Morin, LL, Ebel, GD, et al. A newly emergent genotype of West Nile virus is transmitted earlier and more efficiently by Culex mosquitoes. Am J Trop Med Hyg 2007; 77:365-370.
87. Moutailler, S, Krida, G, Schaffner, F, Vazeille, M, et al. Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonot Dis 2008; 8:749-753.
88. Muller, R, Saluzzo, JF, Lopez, N, Dreier, T, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995; 53:405-411.
89. Naslund, J, Lagerqvist, N, Habjan, M, Lundkvist, A, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009; 385:409-415.
90. Ozkurt, Z, Kiki, I, Erol, S, Erdem, F, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006; 52:207-215.
91. Perera, R, Khaliq, M, Kuhn, RJ. Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res 2008; 80:11-22.
92. Peters, CJ, Reynolds, JA, Slone, TW, Jones, DE, et al. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res 1986; 6:285-297.
93. Pittman, PR, Liu, CT, Cannon, TL, Makuch, RS, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999; 18:181-189.
94. Sall, AA, Zanotto, PM, Sene, OK, Zeller, HG, et al. Genetic re-assortment of Rift Valley fever virus in nature. J Virol 1999; 73:8196-8200.
95. Sardelis, MR, Turell, MJ, Dohm, DJ, O'Guinn, ML. Vector competence of selected North American Culex and Coquillettidia mosquitoes for West Nile virus. Emerg Infect Dis 2001; 7:1018-1022.
96. Schmaljohn, CS, Parker, MD, Ennis, WH, Dalrymple, JM, et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 1989; 170:184-192.
97. Schmaljohn, CS, Hooper, JW. Bunyaviridae: the viruses and their replication. In: B.N. Fields, D.M. Knipe, P.M. Howley, and D.E. Griffin ed. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001.
98. Sharifi-Mood, B, Metanat, M, Ghorbani-Vaghei, A, Fayyaz-Jahani, F, et al. The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch Iran Med 2009; 12:151-153.
99. Shi, X, Elliott, RM. Generation and analysis of recombinant Bunyamwera orthobunyaviruses expressing V5 epitope-tagged L proteins. J Gen Virol 2009; 90:297-306.
100. Siger, L, Bowen, RA, Karaca, K, Murray, MJ, et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res 2004; 65:1459-1462.
101. Smithburn, KC. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 1949; 30:1-16.
102. Smithburn, KC, Haddow, AJ, Lumsden, WH. Rift Valley fever; transmission of the virus by mosquitoes. Br J Exp Pathol 1949; 30:35-47.
103. Swanepoel, R, Gill, DE, Shepherd, AJ, Leman, PA, et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11 (SUPPL. 4):S794-S800.
104. Tasdelen Fisgin, N, Ergönül, Ö., Doganci, L, Tulek, N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009; 28:929-933.
105. Tignor, GH, Hanham, CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res 1993; 22:309-325.
106. Turell, MJ, Dohm, DJ, Mores, CN, Terracina, L, et al. Potential for North American mosquitoes to transmit Rift Valley fever virus. J Am Mosq Control Assoc 2008; 24:502-507.
107. Wallace, DB, Ellis, CE, Espach, A, Smith, SJ, et al. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006; 24:7181-7189.
108. Watts, DM, Ussery, MA, Nash, D, Peters, CJ. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 1989; 41:581-585.
109. WHO. Outbreak news. Rift Valley fever, Madagascar. Wkly Epidemiol Rec 2008; 83:157.
110. WHO. Outbreak news. Rift Valley fever, Sudan-update. Wkly Epidemiol Rec 2007a; 82:417-418.
111. WHO. Outbreaks of Rift Valley fever in Kenya, Somalia and United Republic of Tanzania. December 2006-April 2007. Wkly Epidemiol Rec 2007b; 82:169-178.
112. Willadsen, P. Anti-tick vaccines in "Ticks, Disease and Control." Parasitology 2004; (SUPPL.) 129:S367-S388.
113. Willadsen, P. The molecular revolution in the development of vaccines against ectoparasites. Vet Parasitol 2001; 101:353-368.
114. Willadsen, P, Bird, P, Cobon, GS, Hungerford, J. Commercialisation of a recombinant vaccine against Boophilus microplus. Parasitology 1995; 110 (SUPPL.):S43-S50.
115. Willadsen, P, Riding, GA, McKenna, RV, Kemp, DH, et al. Immunologic control of a parasitic arthropod. Identification of a protective antigen from Boophilus microplus. J Immunol 1989; 143:1346-1351.